| Date | Form | Description | Docs | XBRL | Pages |
| 03/17/98 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
13 | |
| 01/29/98 | 10-K405 | Annual report [Sections 13 and 15(d), S-K Item 405] |
|
40 | |
| 09/12/97 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
17 | |
| 06/23/97 | DEF 14A | Definitive proxy statements |
|
9 | |
| 06/13/97 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
15 | |
| 06/09/97 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
10 | |
| 03/14/97 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
26 | |
| 01/31/97 | 10-K405/A | Annual report [Sections 13 and 15(d), S-K Item 405] |
|
2 | |
| 01/29/97 | 10-K405 | Annual report [Sections 13 and 15(d), S-K Item 405] |
|
35 | |
| 11/27/96 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
11 |
Latest News & Events
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Read More...Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Read More...Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Read More...